person · Reporting owner

CHILDS JOHN W

Disclosed activity across 4 companies

Tapewire entity: 23486
SEC CIK: 0001027035

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Biohaven Ltd.BHVN · Entity 4379	Director	April 28, 2026	May 01, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269	Director	October 03, 2022	October 04, 2022
Veradermics, IncMANE · Entity 1907	Director	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Biohaven Ltd.

Report date April 28, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28	Direct	68,693	Reported balance After 2026-04-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 04, 2022

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2022-10-03 transaction · row 1 1 source row Row 1 · 2022-10-03 · Disposition to issuer · Disposed 3,025,001 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Common SharesSEC Table I · non-derivative	IndirectBy John W Childs 2013 Revocable Trust	Reported balance After 2022-10-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28	Direct	Reported balance After 2022-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05	Direct	Reported balance After 2022-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Veradermics, Inc

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	279,117	Reported balance After 2026-08-12 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-08-12 · Sale · Disposed 15,000 · Balance 279,117 F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	199,117	Reported balance After 2026-08-12 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-08-12 · Sale · Disposed 80,000 · Balance 199,117 F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	194,117	Reported balance After 2026-08-12 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-08-12 · Sale · Disposed 5,000 · Balance 194,117 F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,907,889	Reported balance Holding disclosure · report date 2026-08-12 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,907,889 F4: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MATTRESS FIRM HOLDING CORP.

Report date September 14, 2016 · Filed September 16, 2016

Jointly reported with J.W. Childs Associates, Inc., J.W. Childs Associates, L.P., J.W. Childs Advisors III, L.P., Winter Street Opportunities Fund, L.P., JWC FUND III CO INVEST LLC, JWC Mattress Holdings, LLC

Section 16 reporting ended · disclosed 2016-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2016-09-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-09-14 · Other · Disposed 540,653 · Balance 0 F1: Represents shares directly held by Winter Street Opportunities Fund, L.P. ("WSOF"). J.W. Childs Advisors III, L.P. ("GPLP") is the general partner of WSOF. J.W. Childs Associates, L.P. ("JWC Associates LP") is the general partner of GPLP. J.W. Childs Associates, Inc. ("JWC Associates Inc.") is the general partner of JWC Associates LP. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than WSOF) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2016-09-14 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2016-09-14 · Other · Disposed 18,787 · Balance 0 F2: Represents shares directly held by JWC Fund III Co-Invest, LLC ("Co-Invest III"). WSOF holds approximately 26% of the membership interests in Co-Invest III. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Co-Invest III) disclaims pecuniary interest in the reported securities except to the extent of his economic interest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2016-09-14 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2016-09-14 · Other · Disposed 12,713,589 · Balance 0 F3: Represents shares directly held by JWC Mattress Holdings, LLC ("Mattress Holdings"). WSOF and Co-Invest III hold approximately 97.3% and approximately 2.7%, respectively, of the membership interests in Mattress Holdings. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of each of Mattress Holdings and Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Mattress Holdings) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2016-09-14 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2016-09-14 · Other · Disposed 326,251 · Balance 0 F4: Represents shares directly held by the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs is the sole trustee of the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs disclaims pecuniary interest in the reported securities except to the extent of his economic interest.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares directly held by Winter Street Opportunities Fund, L.P. ("WSOF"). J.W. Childs Advisors III, L.P. ("GPLP") is the general partner of WSOF. J.W. Childs Associates, L.P. ("JWC Associates LP") is the general partner of GPLP. J.W. Childs Associates, Inc. ("JWC Associates Inc.") is the general partner of JWC Associates LP. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than WSOF) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.

F2: Represents shares directly held by JWC Fund III Co-Invest, LLC ("Co-Invest III"). WSOF holds approximately 26% of the membership interests in Co-Invest III. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Co-Invest III) disclaims pecuniary interest in the reported securities except to the extent of his economic interest.

F3: Represents shares directly held by JWC Mattress Holdings, LLC ("Mattress Holdings"). WSOF and Co-Invest III hold approximately 97.3% and approximately 2.7%, respectively, of the membership interests in Mattress Holdings. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of each of Mattress Holdings and Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Mattress Holdings) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.

F4: Represents shares directly held by the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs is the sole trustee of the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs disclaims pecuniary interest in the reported securities except to the extent of his economic interest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	Exercise / conversionStock Options (Right to Buy) · Derivative	5,998	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 8 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	Exercise / conversionStock Options (Right to Buy) · Derivative	4,119	$0.00 Strike: $4.84	$0.00	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 7 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	OtherStock Options (Right to Buy) · Derivative	5,998	Not disclosed Strike: $3.56	Not disclosed	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 6 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	OtherStock Options (Right to Buy) · Derivative	4,119	Not disclosed Strike: $4.84	Not disclosed	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 5 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	Tax withholdingCommon Shares	5,507	$7.50	$41,302.50	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,522,110 F2 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	Exercise / conversionCommon Shares	5,998	$3.56	$21,352.88	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	Exercise / conversionCommon Shares	4,119	$4.84	$19,935.96	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC	Biohaven Ltd. BHVN · Entity 4379	OtherCommon Shares	1,517,500	$0.00	$0.00	Disclosure SEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517,500 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document
April 28, 2022 Filed Apr 30, 2022 01:02 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	8,239	$0.00 Strike: $97.74	$0.00	Disclosure SEC source: 0001562180-22-003586 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,239 Underlying: Common Shares · 8,239 shares Expires 2032-04-27 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $47.10	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 15 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $10.82	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 14 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on April 6, 2017, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $61.76	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 13 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $28.76	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 12 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	37,700	$0.00 Strike: $9.29	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 11 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 37,700 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 15, 2016, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $5.60	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 10 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on October 23, 2015, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionStock Option (Right to Buy) · Derivative	212,500	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · derivative · entry 9 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 212,500 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on November 26, 2014, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	18,000	$47.10	$847,800.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 7 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,025,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	20,000	$10.82	$216,400.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 6 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	18,000	$61.76	$1,111,680.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 5 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,987,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	18,000	$28.76	$517,680.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	37,700	$9.29	$350,233.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,951,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	150,000	$5.60	$840,000.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2021 Filed Nov 18, 2021 00:03 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	212,500	$0.61	$129,625.00	Disclosure SEC source: 0001562180-21-007139 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,763,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 10, 2021 Filed Nov 10, 2021 23:19 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	1,110	$123.30	$136,862.00	Disclosure SEC source: 0001562180-21-006983 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550,801 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $123.16 - $123.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
November 10, 2021 Filed Nov 10, 2021 23:19 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	3,890	$122.75	$477,480.00	Disclosure SEC source: 0001562180-21-006983 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549,691 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $122.45 - $123.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 05, 2021 Filed May 7, 2021 20:34 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	11,996	$0.00 Strike: $71.94	$0.00	Disclosure SEC source: 0001562180-21-003339 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,996 Underlying: Common Shares · 11,996 shares Expires 2031-05-04 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document
March 17, 2021 Filed Mar 17, 2021 21:13 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	13,157	$76.00	$999,932.00	Disclosure SEC source: 0001562180-21-002300 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,801 Read SEC document
March 02, 2021 Filed Mar 4, 2021 02:22 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	10,000	$85.14	$851,370.00	Disclosure SEC source: 0001562180-21-001959 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,532,644 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $84.93 - $85.335, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
January 25, 2021 Filed Feb 13, 2021 02:51 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	OtherCommon Shares	5,706	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001147 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522,644 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of January 1, 2021, by and among Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Kleo Acquisition, Inc., Kleo Pharmaceuticals, Inc. ("Kleo") and Shareholder Representative Services LLC, on January 25, 2021, common shares of the Issuer were received in exchange for shares of common stock of Kleo held by the Reporting Person. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 1, 2021, by and among Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Kleo Acquisition, Inc., Kleo Pharmaceuticals, Inc. ("Kleo") and Shareholder Representative Services LLC, on January 25, 2021, common shares of the Issuer were received in exchange for shares of common stock of Kleo held by the Reporting Person. Read SEC document
November 23, 2020 Filed Nov 24, 2020 01:40 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	5,000	$89.55	$447,736.50	Disclosure SEC source: 0001562180-20-006851 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,516,938 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $89.36- $90.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
September 21, 2020 Filed Sep 23, 2020 01:51 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	3,322	$59.25	$196,828.50	Disclosure SEC source: 0001562180-20-006075 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511,938 Read SEC document
September 11, 2020 Filed Sep 15, 2020 00:49 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	6,678	$59.00	$393,983.97	Disclosure SEC source: 0001562180-20-005986 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508,616 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $58.93 - $59.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
August 11, 2020 Filed Aug 12, 2020 22:25 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	15,129	$61.87	$936,093.26	Disclosure SEC source: 0001562180-20-005409 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501,938 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $61.71 - $62.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
August 11, 2020 Filed Aug 12, 2020 22:25 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	7,271	$61.28	$445,567.61	Disclosure SEC source: 0001562180-20-005409 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486,809 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $60.71 - $61.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
August 11, 2020 Filed Aug 12, 2020 22:25 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	2,600	$60.32	$156,823.94	Disclosure SEC source: 0001562180-20-005409 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,479,538 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $59.69 - $60.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 30, 2020 Filed May 2, 2020 01:14 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $47.10	$0.00	Disclosure SEC source: 0001562180-20-003256 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document
April 07, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	14,734	$33.26	$490,119.14	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 6 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,476,938 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 - $33.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 07, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	93,268	$32.92	$3,070,130.74	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 5 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,491,672 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.11 - $33.105, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 07, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	10,908	$31.55	$344,196.49	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,940 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.095 - $32.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 07, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	81,090	$30.54	$2,476,585.91	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595,848 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.095 - $31.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 06, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	5,341	$31.76	$169,626.96	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 - $31.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
April 06, 2020 Filed Apr 9, 2020 01:42 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	SaleCommon Shares	144,659	$31.23	$4,517,309.99	Disclosure SEC source: 0001562180-20-002967 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,682,279 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.70 - $31.6925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
June 26, 2019 Filed Jun 27, 2019 00:40 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	10,000	$40.37	$403,700.00	Disclosure SEC source: 0001209191-19-039192 · doc4.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 10,000 Read SEC document
May 21, 2019 Filed May 23, 2019 22:36 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $61.76	$0.00	Disclosure SEC source: 0001209191-19-032468 · doc4.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document
March 22, 2019 Filed Apr 5, 2019 21:53 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionWarrant to Purchase Common Shares (Right to Buy) · Derivative	107,500	$0.00 Strike: $9.29	$0.00	Disclosure SEC source: 0001209191-19-023859 · doc4.xml · derivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 107,500 shares Expires 2019-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document
March 22, 2019 Filed Apr 5, 2019 21:53 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	Exercise / conversionCommon Shares	107,500	$9.29	$998,675.00	Disclosure SEC source: 0001209191-19-023859 · doc4.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2018 Filed May 3, 2018 21:24 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $28.76	$0.00	Disclosure SEC source: 0001209191-18-027730 · doc4.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document
May 09, 2017 Filed May 9, 2017 20:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	ConversionSeries A Preferred Shares · Derivative	1,035,938	$0.00	$0.00	Disclosure SEC source: 0001209191-17-030981 · doc4.xml · derivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the John W. Childs 2013 Revocable Trust Disclosed balance after: 0 Underlying: Common Shares · 1,035,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. F2 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. F2 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date. Read SEC document
May 09, 2017 Filed May 9, 2017 20:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	PurchaseCommon Shares	415,000	$17.00	$7,055,000.00	Disclosure SEC source: 0001209191-17-030981 · doc4.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the John W. Childs 2013 Revocable Trust Disclosed balance after: 2,719,438 Read SEC document
May 09, 2017 Filed May 9, 2017 20:47 UTC	Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269	ConversionCommon Shares	1,035,938	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-030981 · doc4.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the John W. Childs 2013 Revocable Trust Disclosed balance after: 2,304,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares received upon conversion of Series A Preferred Shares. F1 · price: Represents shares received upon conversion of Series A Preferred Shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.